Estructura del complejo del inhibidor tipo antistasina bdelastasina con tripsina y modelado del sistema bdelastasina-microplasmina

The serine proteinase plasmin is, together with tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), involved in the dissolution of blood clots in a fibrin-dependent manner. Moreover, plasmin plays a key role in a variety of other activation cascades such as the activation of metalloproteinases, and has also been implicated in wound healing, pathogen invasion, cancer invasion and metastasis. The leech-derived (Hirudo medicinalis) antistasin-type inhibitor bdellastasin represents a specific inhibitor of trypsin and plasmin and thus offers a unique opportunity to evaluate the concept of plasmin inhibition. The complexes formed between bdellastasin and bovine as well as porcine beta-trypsin have been crystallised in a monoclinic and a tetragonal crystal form, containing six molecules and one molecule per asymmetric unit, respectively. Both structures have been solved and refined to 3.3 A and 2.8 A resolution. Bdellastasin turns out to have an antistasin-like fold exhibiting a bis-domainal structure like the tissue kallikrein inhibitor hirustasin. The interaction between bdellastasin and trypsin is restricted to the C-terminal subdomain of bdellastasin, particularly to its primary binding loop, comprising residues Asp30-Glu38. The reactive site of bdellastasin differs from other antistasin-type inhibitors of trypsin-like proteinases, exhibiting a lysine residue instead of an arginine residue at P1. A model of the bdellastasin-microplasmin complex has been created based on the X-ray structures. Our modelling studies indicate that both trypsin and microplasmin recognise bdellastasin by interactions which are characteristic for canonically binding proteinase inhibitors. On the basis of our three-dimensional structures, and in comparison with the tissue-kallikrein-bound and free hirustasin and the antistasin structures, we postulate that the binding of the inhibitors toward trypsin and plasmin is accompanied by a switch of the primary binding loop segment P5-P3. Moreover, in the factor Xa inhibitor antistasin, the core of the molecule would prevent an equivalent rotation of the P3 residue, making exosite interactions of antistasin with factor Xa imperative. Furthermore, Arg32 of antistasin would clash with Arg175 of plasmin, thus impairing a favourable antistasin-plasmin interaction and explaining its specificity.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Bdelastasina de Hirudo medicinalis es un inhibidor específico de tripsina y plasmina. Los complejos con β-tripsina se resolvieron a 3,3 Å y 2,8 Å; el inhibidor presenta plegamiento tipo antistasina con dos dominios, como hirustasina, interactúa por el subdominio C-terminal y lleva Lys en P1 en lugar de Arg. Se creó un modelo del complejo bdelastasina-microplasmina. Los autores postulan que Arg32 de antistasina chocaría con Arg175 de la plasmina, lo que impediría una interacción favorable y explicaría su especificidad.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Genómica y proteómica».

• Leech Salivary Proteome and Transcriptome: 434 Deduced Protein Sequences — Liu Z, Tong X, Su Y, et al. (2019)
• Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
• La terapia con sanguijuelas (Hirudo medicinalis) atenúa las lesiones testiculares inducidas por isquemia/reperfusión testicular en un modelo animal — Davoodi F et al. (2021)
• Nueva proteína anticoagulante de la sanguijuela medicinal — Manuvera V et al. (2024)
• AIF-1 y RNASET2 desempeñan papeles complementarios en la respuesta inmunitaria innata de la sanguijuela medicinal — Baranzini N et al. (2019)
• Los péptidos antimicrobianos de la sanguijuela medicinal carentes de toxicidad representan una estrategia alternativa prometedora para combatir patógenos resistentes a antibióticos — Grafskaia E et al. (2019)
• Perspectivas estructurales sobre la actividad trombolítica de la destabilasa de la sanguijuela medicinal — Marin E et al. (2023)
• El genoma de la sanguijuela medicinal (Whitmania pigra) y un estudio genómico comparativo para la exploración de ingredientes bioactivos — Tong L et al. (2022)
• El SNC de la sanguijuela medicinal como modelo para estudios de exosomas en la comunicación cruzada entre microglía y neuronas — Raffo-Romero A et al. (2018)
• Transcriptomic profiling and the first spatial expression analysis of candidate genes in the salivary gland of the East Asian medicinal leech, Hirudo nipponia — Kim J et al. (2024)

Ver toda la investigación analizada por la ASH →